Methods for treating cancer
The present invention relates to a method of treating cancer in a subject.
1. A method of treating cancer in a patient, wherein the cancer is selected from the group consisting of a sarcoma, lung cancer, breast cancer, colon cancer, gastric cancer, and head and neck cancer, comprising administering to said patient a therapeutically effective amount of BT1718, or a pharmaceutically acceptable salt and/or composition thereof,
wherein
the sarcoma is an N-ras mutant/IDH1 mutant soft tissue sarcoma (STS);
the lung cancer is a Met-amplified squamous NSCLC, a Squamous cell NSCLC with wt EGFR, or a T790M EGFR-expressing lung adenocarcinoma;
the breast cancer is a triple negative breast cancer;
the colon cancer is a colorectal adenocarcinoma;
the gastric cancer is a FGFR-amplified gastric cancer; and
the head and neck cancer is a nasal septum squamous cell carcinoma,
and wherein BT1718 is a Bicycle drug conjugate of formula:
2. The method of claim 1 , wherein the cancer is an N-ras mutant/IDH1 mutant soft tissue sarcoma (STS).
3. The method of claim 1 , wherein the cancer is a triple negative breast cancer.
4. The method of claim 3 , wherein the triple negative breast cancer is a basaloid triple negative breast cancer.
5. The method of claim 1 , wherein the cancer is a colorectal adenocarcinoma.
6. The method of claim 1 , wherein the cancer is a FGFR-amplified gastric cancer.
7. The method of claim 1 , wherein the cancer is a nasal septum squamous cell carcinoma.
8. A method of treating cancer in a patient, wherein the cancer is selected from the group consisting of a sarcoma, lung cancer, breast cancer, colon cancer, gastric cancer, and head and neck cancer, comprising administering to said patient a minimally effective dose of BT1718, or a pharmaceutically acceptable salt and/or composition thereof, wherein the minimally effective dose leads to tumor-stasis when administered intravenous twice a week (IV BIW),
wherein
the sarcoma is an N-ras mutant/IDH1 mutant soft tissue sarcoma (STS);
the lung cancer is a Met-amplified squamous NSCLC, a Squamous cell NSCLC with wt EGFR, or a T790M EGFR-expressing lung adenocarcinoma;
the breast cancer is a triple negative breast cancer;
the colon cancer is a colorectal adenocarcinoma;
the gastric cancer is a FGFR-amplified gastric cancer; and
the head and neck cancer is a nasal septum squamous cell carcinoma,
and wherein BT1718 is a Bicycle drug conjugate of formula:
9. The method of claim 8 , wherein the cancer is a triple negative breast cancer, and the minimally effective dose is <10 mg/kg.
10. The method of claim 8 , wherein the cancer is a FGFR-amplified gastric cancer, and the minimally effective dose is 3 mg/kg.
11. The method of claim 8 , wherein the cancer is an N-ras mutant/IDH1 mutant soft tissue sarcoma (STS), and the minimally effective dose is <3 mg/kg.
12. The method of claim 8 , wherein the cancer is a basaloid triple negative breast cancer, and the minimally effective dose is <10 mg/kg.
13. The method of claim 8 , wherein the cancer is a high pgp-expressing colorectal adenocarcinoma, and the minimally effective dose is >10 mg/kg.
14. The method of claim 8 , wherein the cancer is a colorectal adenocarcinoma, and the minimally effective dose is 10 mg/kg.
15. The method of claim 8 , wherein the cancer is a nasal septum squamous cell carcinoma, and the minimally effective dose is 10 mg/kg.
16. The method of claim 8 , wherein the cancer is a Met-amplified squamous NSCLC, and the minimally effective dose is <10 mg/kg.
17. The method of claim 8 , wherein the cancer is a Squamous cell NSCLC with wt EGFR, and the minimally effective dose is <10 mg/kg.
18. The method of claim 8 , wherein the cancer is a T790M EGFR-expressing lung adenocarcinoma, and the minimally effective dose is <10 mg/kg.
19. The method of claim 5 , wherein the colorectal adenocarcinoma is a high pgp-expressing colorectal adenocarcinoma.
20. The method of claim 1 , wherein the cancer is a Met-amplified squamous NSCLC.
21. The method of claim 1 , wherein the cancer is a Squamous cell NSCLC with wt EGFR.
22. The method of claim 1 , wherein the cancer is a T790M EGFR-expressing lung adenocarcinoma.